Asthma Biologics Self-Assessment

This Asthma Biologics self-assessment module is designed to help allergy/immunology providers obtain new knowledge, as well as reaffirm existing knowledge. It also helps allergists/immunologists evaluate and maintain their clinical competence. The module consists of 12 case-based, multiple-choice questions. Comprehensive discussions provide evidence-based explanations regarding all answer options, as well as provides supporting references from the current literature. The questions address the use of biologics for treating asthma, including: safety, patient selection, sides effects and monitoring.

There are 3 modes within this module: Pretest, Learn, and Posttest.

Pretest: This initial self-audit allows for one to identify their gaps in knowledge related to established knowledge regarding the use of biologics for asthma. Answer each question once and receive a Pretest Score at the end.

Learn: This study mode allows one to answer questions, review evidence-based discussions, and link to PubMed abstracts of the references. Answer each question until the correct answer is chosen, then read the discussion and view the references. If you answer incorrectly, you will be given a brief statement on why that answer choice is incorrect. The comprehensive discussion includes rationale for all answer options, whether they are correct or incorrect.

Posttest: This final audit allows one to measure the amount of learning that has occurred. Answer each question once and receive a Posttest Score at the end. One has 3 attempts to achieve a passing score of 80% or better.

The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 3.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABAI designates this program for 3.5 ABAI MOC Part II (Self-Assessment) credits.

Commercial Support
There is no commercial support for this activity.


Target Audience

Practicing Allergy/Immunology Providers and Fellows in Training.

Learning Objectives

At the conclusion of this course, participants should be able to:

  • Demonstrate a mastery of key concepts relating to the use of biologics for treating asthma
  • Evaluate safety and patient appropriateness for biologic therapy
  • Monitor for and identify possible sides effects of biological therapy
Additional information

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines a “ineligible company” as companies whose primary business is producing, marketing, selling, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include: 
•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.
Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.
Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified relevant financial relationships have been mitigated.

Course summary
Available credit: 
  • 3.50 AMA PRA Category 1 Credit™
  • 3.50 Attendance
  • 3.50 MOC
Course opens: 
Course expires: 

All relevant financial relationships have been resolved.

Karen Anstey, MD
Dr. Anstey is an Assistant Professor of Medicine at Oregon Health and Science University. She is the Associate Program Director of the Allergy/Immunology Fellowship at OHSU as well as Thread Director of Health Systems Science within OHSU School of Medicine. 
Dr. Anstey discloses the following financial relationships: Sanofi: Speaker; GSK: Researcher.

Rana T. Misiak, MD, FACAAI 
Dr. Misiak is the Senior Staff Physician, Allergy and Immunology, at Henry Ford Health in Dearborn, Michigan. She is a Clinical Assistant Professor at Wayne State University School of Medicine in Detroit, Michigan.
Dr. Misiak has no relevant financial relationships to disclose.

Ellen Stephen, MD 
Dr. Stephen is an Assistant Professor in the Rush University Medical Center Division of Allergy/Immunology in Chicago, Illinois. She completed her residency in Internal Medicine at the University of Chicago and Allergy/Immunology fellowship at Rush University.
Dr. Stephan has no relevant financial relationships to disclose.

Joel Klein, MD, FACAAI
Dr. Klein is Vice-Chairperson of the Clinical Programs/Patient Safety and Quality Committee of the ACAAI.  He is in private practice in Highland Park, IL and is a Clinician Educator at the University of Chicago Pritzker School of Medicine.
Dr. Klein has no relevant financial relationships to disclose.

Available Credit

  • 3.50 AMA PRA Category 1 Credit™
  • 3.50 Attendance
  • 3.50 MOC


Please login or create an account to take this course.